Clinical pharmacogenomic testing of <it>KRAS, BRAF </it>and <it>EGFR </it>mutations by high resolution melting analysis and ultra-deep pyrosequencing
<p>Abstract</p> <p>Background</p> <p>Epidermal growth factor receptor (<it>EGFR</it>) and its downstream factors <it>KRAS </it>and <it>BRAF </it>are mutated in several types of cancer, affecting the clinical response to EGFR inhibitor...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-09-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/11/406 |